- Home
- WSC vs VRDN Comparison
WSC vs VRDN Comparison
Compare WSC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSC | VRDN |
|---|---|---|
| Founded | 1944 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WSC | VRDN |
|---|---|---|
| Price | $18.68 | $28.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $24.14 | ★ $40.92 |
| AVG Volume (30 Days) | ★ 1.8M | 991.0K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,281,446,000.00 | $5,706,000.00 |
| Revenue This Year | N/A | $27.65 |
| Revenue Next Year | $3.49 | $253.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.91 | $9.90 |
| 52 Week High | $31.88 | $34.29 |
Technical Indicators
Market Signals| Indicator | WSC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 46.63 |
| Support Level | $18.49 | $26.31 |
| Resistance Level | $22.78 | $33.71 |
| Average True Range (ATR) | 0.77 | 1.08 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 63.34 | 46.52 |
Price Performance
Historical ComparisonAbout WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).